- Six Presentations Highlighting the Potential of Epicutaneous Immunotherapy (EPIT®) in the Treatment of Food Allergies
- Late-Breaking Oral Presentation by Pr. Hugh Sampson on VIPES results
- Keynote Oral Presentation by Pr. Christophe Dupont on EPIT®
Bagneux, France, February 3, 2015 - DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that six abstracts on Epicutanous Immunotherapy (EPIT®) were selected for presentation at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI; http://annualmeeting.aaaai.org/) Annual Meeting in Houston, Texas, February 20-24, 2015. The presentations will include detailed results from the Phase 2b trial of Viaskin® Peanut, as well as key preclinical data on EPIT's mechanism of action.
The abstracts will also be published in the February 2015 supplement of the Journal of Allergy and Clinical Immunology (JACI). All abstracts are available online at http://www.jacionline.org/.
On February 24th at 5pm CST, DBV be will providing an investor and analyst briefing in Houston, Texas. This event will be webcasted live. Details for this event will be posted on the DBV website at www.dbv-technologies.com.
| Title | Epicutaneous Immunotherapy (EPIT®) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial |
| Date | February 24 - 2:00 pm to 3:15pm |
| Presenter | Pr. Hugh A. Sampson from Kurt Hirschhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center in New York (USA) |
| Session Name | Food Allergy, Innate Immunity and Genetics of Atopic Dermatitis |
| Session | Poster Number: L28, Session Number: 5611 |
| Link | http://www.jacionline.org/article/S0091-6749%2814%2903701-4/fulltext |
| Type of Session | Late Breaking Oral Abstract Session |
| Title | EPIT® for Food Allergy as an Alternative Pathway for Oral Tolerance Induction |
| Date | February 21 - 4:45 pm to 6:00 pm |
| Presenter | Pr. Christophe Dupont, Head of the Pediatric-Gastroenterology Ambulatory Department at Necker Hospital, Paris, France |
| Session | Food Immunotherapy: What is the Best Method? |
| Type of Session | Oral Presentation |
| Location | Convention Center, Level Three, General Assembly Theater A |
| Title | Larger and Stronger Expression of Tregs Gut Homing Receptors with EPIT than with Sublingual or Oral Immunotherapy |
| Date | February 22 - 3:15 pm to 3:30 pm |
| Presenter | Dr. Vincent Dioszeghy, Researcher at DBV Technologies |
| Session Name | Peptide and Epicutaneous Immunotherapy |
| Session | Poster Number: 518, Session Number: 3606 |
| Type of Session | Oral poster session |
| | |
| Title | Epicutaneous Immunotherapy Prevents from Induction of Anaphylaxis to Further Allergen |
| Date | February 22 - 9:45am to 10:45am |
| Presenter | Dr. Lucie Mondoulet, Head of Research at DBV Technologies |
| Session Name | Peptide and Epicutaneous Immunotherapy |
| Session | Number: 467, Session Number: 3212 |
| Type of Session | Poster Session |
| Tittle | Epigenetic Changes Following Epicutaneous Immunotherapy in Peanut Sensitized Mice |
| Date | Sunday, February 22, 2015 between 9:45am to 10:45am |
| Presenter | Dr. Lucie Mondoulet |
| Session Name | Peptide and Epicutaneous Immunotherapy |
| Session | Number: 466, Session Number: 3212 |
| Type of Session | Poster Session |
| Tittle | Epicutaneous but Not Oral Immunotherapy Induces Antigen-Specific Gastrointestinal Tregs and Protects Against Food-Induced Anaphylaxis |
| Date | Monday, February 23, 2015 between: 9:45am to 10:45am |
| Presenter | Dr. Leticia Tordesillas from Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, USA |
| Session Name | Mechanisms of T Cells and Signaling in Disease |
| Session | Number: 732, Session Number: 4211 |
| Type of Session | Poster Session |
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements about the safety and efficacy of Epicutenaous Immunotherapy (EPIT) via Viaskin, including the potential to prevent sensitizations in other allergens, the potential to induce a sustained protection effect and the potential to influence the natural history of allergy. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular it should be noted that these data are preclinical in nature and have not been demonstrated in human subjects. The company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on October 22, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.
DBV Technologies Contacts
| Susanna Mesa VP Finance, US Investor Relations & Strategy Tel. : +1 917-346-3447 susanna.mesa@dbv-technologies.com DBV IR and Media Contacts | Nathalie Donne Director, Corporate Communication & Business Development Tel. : +33(0)1 55 42 78 72 nathalie.donne@dbv-technologies.com | |||||
| Marion Janic US Media Relations Rooney & Associates Tel. : +1-212-223-4017 mjanic@rooneyco.com | ||||||
